JY
EIGR

Jeff Yass’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Jeff Yass’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-757
Closed -$171K – 14068
2022
Q3 		$171K Buy
+757
New +$186K ﹤0.01% 11069
2022
Q2 		– Sell
-1,307
Closed -$325K – 14245
2022
Q1 		$325K Sell
1,307
-290
-18% -$45.8K ﹤0.01% 10084
2021
Q4 		$249K Sell
1,597
-80
-5% -$15.5K ﹤0.01% 10956
2021
Q3 		$336K Buy
1,677
+110
+7% +$26.2K ﹤0.01% 10334
2021
Q2 		$400K Sell
1,567
-1,843
-54% -$460K ﹤0.01% 10136
2021
Q1 		$905K Sell
3,410
-1,600
-32% -$504K ﹤0.01% 7997
2020
Q4 		$1.85M Sell
5,010
-2,197
-30% -$630K ﹤0.01% 5261
2020
Q3 		$1.76M Buy
+7,207
New +$2.24M ﹤0.01% 4877
2020
Q2 		– Sell
-380
Closed -$78K – 11148
2020
Q1 		$78K Sell
380
-27
-7% -$8.61K ﹤0.01% 9471
2019
Q4 		$182K Buy
+407
New +$144K ﹤0.01% 8832
2015
Q4 		– Sell
-96
Closed -$46K – 10106
2015
Q3 		$46K Sell
96
-332
-78% -$176K ﹤0.01% 9384
2015
Q2 		$243K Sell
428
-224
-34% -$620K ﹤0.01% 8943
2015
Q1 		$5.55M Buy
+652
New +$5.7M ﹤0.01% 2591

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $412M AUM 15.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return

Jeff Yass's EIGR Position: Q1 2024 in Review

Jeff Yass sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 850 shares — an estimated $5.73K sold.

Jeff Yass first reported a position in EIGR in Q4 2014 and held it in 22 quarters. The position peaked at $1.27M in Q1 2019. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Jeff Yass reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Jeff Yass sold 850 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $5.73K.
  • Jeff Yass first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 22 quarters.
  • Jeff Yass's Eiger BioPharmaceuticals, Inc. position peaked at $1.27M in Q1 2019.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.